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ABSTRACT
Background
Fifty to sixty percent of patients with essential thrombocythemia harbor the JAK2V617F mutation.
The impact of this mutation on clinical phenotype is still debated. The aim of this study was to
evaluate possible correlations between JAK2V617F mutant allele burden and both clinical pres-
entation and hematologic abnormalities in essential thrombocythemia patients.
Design and Methods
In this single-center retrospective study, JAK2V617F allele load was measured by sensitive quan-
titative reverse transcriptase polymerase chain reaction (RT-PCR) in the granulocytes of 260
patients diagnosed as having essential thrombocythemia according to WHO criteria.
Results
Median V617F allele burden in patients with the mutation (n=165, 63.4%) was 24%, ranging
from 1% to 87%; an allele burden greater than 51% was found in 5% of the patients. Older
patients presented progressively higher percentages of the V617F allele. Signs of stimulated
erythropoiesis and myelopoiesis, as well as higher PRV-1 levels, were found in patients with
the mutation, but no linear correlation with load of mutant allele could be ascertained; on the
other hand, the frequency of patients with erythropoietin-independent erythroid colonies pro-
gressively increased depending on mutant allele load. Splenomegaly and microvessel symp-
toms were significantly more represented among patients with greater than 50% and 25%
JAK2V617F allele burden, respectively. Increasing mutant allele load correlated with higher fre-
quency of arterial thrombosis at diagnosis, as confirmed also in multivariate analysis; the rel-
ative risk was 3.0 (95% CI 1.3-6.8; p=0.01) in patients having a greater than 25% mutant
allele burden.
Conclusions
The JAK2V617F mutant allele burden contributes to determining the clinical phenotype in patients
with essential thrombocythemia.
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Introduction
An acquired mutation in exon 14 of the Janus tyrosine
kinase 2 gene (JAK2) leading to a valine→phenylalanine
change at position 617 (JAK2V617F) in the JH2 pseudo-
kinase domain,1-4 has been described in Philadelphia-
negative chronic myeloproliferative disorders (MPD);5,6
it can be found in approximately 95% cases of poly-
cythemia vera (PV) and in approximately 50-60% cases
of of essential thrombocythemia (ET) or primary
myelofibrosis (PMF).7 A role for the gain-of-function8 of
mutant JAK2 in the pathogenesis of MPD is supported
by in vitro studies, which showed growth factor inde-
pendence and enhanced JAK-STAT signaling in cells
transfected with the mutant allele, and by the results of
in vivo animal models.2,9,10 The JAK2V617F mutation can be
harbored in the heterozygous or homozygous state, the
latter deriving from mitotic recombination;1-4 homozy-
gosity for this mutation is found in about 30% of PV
and PMF patients but it is rare (2-4%) in ET.
In patients with the different MPD, the JAK2V617F muta-
tion has been variably associated with higher indices of
erythropoiesis,11,12 unchanged or decreased platelet
counts,11,12 greater occurrence of thrombosis,4,13 bone
marrow fibrosis or cytoreductive treatment,4 older
patients’ age,3,4,14,15 longer disease duration or poorer sur-
vival.16 In particular, in the case of ET, it has been sug-
gested that JAK2V617F mutation imparts patients a PV-like
phenotype;11 furthermore, the risk of thrombosis has
been found to be increased in ET patients with the
mutation,17 particularly in those harboring it in the
homozygous state.13 It is still unclear, however, how the
presence of the JAK2V617F mutation can help the clinician
in identifying categories of patients with unique clinical
and prognostic characteristics. One of the reasons
underlying current uncertainties is that genomic tech-
niques currently employed for detection of the JAK2V617F
mutation do not produce quantitative information
about the level of the mutant allele, which might repre-
sent an important variable influencing disease presenta-
tion. The levels of expression of genes such as PRV-1 and
NFE-2, the number of CD34+ cells in the peripheral blood,
and the concentration of alkaline leukocyte phosphatase
(ALP), have all been shown to be dependent on mutant
allele burden.18-20 A prospective study in PV patients iden-
tified those with greater than 75% V617F allele as having
more pronounced signs of myeloproliferation, a higher
incidence of thrombosis and as being at greater risk of
needing chemotherapy.21
In the current study we explored whether there was
an association between burden of the JAK2 mutation
and clinical presentation in a retrospective series of 260
patients with ET. We correlated the levels of JAK2V617F
allele load in granulocytes with clinical and hematolog-
ic characteristics and with some markers typical of
MPD, which included X-chromosome inactivation pat-
tern (XCIP), PRV-1 expression level and erythropoietin-
independent erythroid colony (EEC) formation.
Additionally, quantitative analysis of the JAK2V617F muta-
tion was performed serially in 35 patients during fol-
low-up to evaluate any fluctuations in mutant allele
load.
Design and Methods
Patients
This study involved 260 patients with a diagnosis of
ET according to WHO criteria,22 115 of whom had been
previously included in a multicenter GIMEMA study.13
The design of this study was that of a retrospective, sin-
gle center study; the only criteria necessary for inclusion
were a diagnosis of ET satisfying the WHO criteria,
complete chart records, and availability of a stored or
fresh granulocyte DNA sample for JAK2 mutational
analysis. If patients had been first genotyped during fol-
low-up, only those not receiving cytoreductive drugs
were considered. All diagnoses were re-evaluated using
the original clinical records and bone marrow biopsies
by an ad hoc panel of four hematologists and two
pathologists. The study was approved by the local
Ethical Committee and informed consent was obtained
from all patients included. 
Clinical outcomes
The presence of splenomegaly was objectively deter-
mined on the basis of an ultrascan demonstrating an
organ with a longitudinal diameter ≥12 cm. Major
thrombotic events, whether arterial or venous (ischemic
stroke, transient ischemic attack, myocardial infarction,
angina pectoris, peripheral arterial thrombosis, deep
vein thrombosis including cerebral and splanchnic
venous thromboses, and pulmonary embolism) were
recorded only if they happened after the diagnosis or in
the preceding 2 years23 and were objectively document-
ed.24 Only major bleeding events were considered, and
included fatal hemorrhages, non-fatal intracranial bleed-
ing or any other hemorrhages requiring surgery or caus-
ing a hemoglobin reduction of ≥2 g/dL and/or needing
transfusion of two or more red blood cell units. The
presence of symptoms due to microvessel disorder
(headache, acral paresthesia, erythromelalgia, transient
neurological and visual disturbances) was routinely
investigated and recorded in the chart records by refer-
ring physicians, but for the purposes of this study they
were considered only in the case that they had been
described by the patient as non-occasional, of recent
onset, and often ameliorated by aspirin. 
Analysis of the JAK2V617F mutation 
Peripheral blood granulocytes were separated by dif-
ferential centrifugation over a Ficoll-Paque gradient, and
contaminating red cells were removed by hypotonic
lysis; DNA was purified using the QIAmp DNA blood
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kit (Qiagen, GmbH, Germany), and quantified with
NanoDrop technology (Wilmington, DE, USA). All
patients were routinely genotyped for the JAK2V617F
mutation by an allele-specific (ASO) polymerase chain
reaction (PCR), using 75 ng granulocyte DNA. To evalu-
ate whether the mutation was carried in the homozy-
gous or heterozygous state, PCR products were digest-
ed with BsaXI restriction enzyme (New England
Biolabs, Hitchin, UK) as described by Baxter et al.1 The
mutant allele burden was measured by a quantitative real
time (QRT)-PCR assay, using 20 ng genomic DNA. PCR
amplification and detection were performed on an ABI
Prism 7300 analyzer (Applied Biosystems) using the fol-
lowing cycling conditions: 10 minutes at 95°C followed
by 40 cycles of 15 s at 95°C and 60 s at 60°C. Primers
flanking the mutant region (forward primer 5'-
AAGCTTTCTCACAAGCATTTGGTTT-3’; reverse
primer 5'-AGAAAGGCATTAGAAAGCCTG TAGTT-3')
were employed together with Taqman probes which
were specific for either the wild type (VIC-5’-TCTC-
CACAGACACATAC-3’MGB) or the mutant JAK2 allele
(FAM-5’- TCCACAGAAACATAC-3’-MGB). All samples
were analyzed in triplicate and the amount of JAK2V617F
allele was calculated by comparison with serial dilutions
of mutant DNA, obtained from a PV patient with 100%
mutant alleles, and wild-type DNA from healthy subjects.
The mean of triplicate DCT determinations
(CTJAK2V617F–CTJAK2WT) was used to calculate the percentage of
mutant alleles. Positive and negative controls were includ-
ed in each assay; inter- and intra-assay variation was 3%
and 5%, respectively.
Other biological markers 
PRV-1 expression level. The level of expression of neu-
trophil PRV-1, and of GAPDH as the housekeeping gene,
was quantified using the Taqman one-step procedure, as
described previously.25 The PRV-1 cycle threshold (CT)
ratio was calculated from the mean value of triplicate
PRV-1 CT determinations divided by the mean of triplicate
GAPDH CT; the PRV-1 CT ratio in healthy blood donors
(n=30) was 1.37±0.09; PRV-1 over-expression was defined
in the presence of a PRV-1/GAPDH CT ratio ≤1.17.
Erythropoietin-independent erythroid colonies. In vitro assays
for EEC was performed by plating 2.5×105 peripheral
blood mononuclear cells in Methocult H4531 medium
(StemCell, Vancouver, Canada) in the absence of added
erythropoietin. Concurrent plates containing optimal
amounts of erythropoietin (2 U/mL) were prepared as
control cultures. Dishes were incubated in a humidified
atmosphere of 5% CO2 at 37°C, and hemoglobinized
colonies were enumerated on day 14 by standard criteria.
Clonal hematopoiesis. XCIP evaluation was performed at
the HUMARA locus in female patients aged less than 60
years old using a PCR assay and enzymatic digestion with
RsaI and HpaII, as described elsewhere.26 Immuno-
magnetically purified CD3+ T-lymphocytes were used as
control cells.
Statistical analysis
Data were processed using the GraphPad InStat
(GraphPad Software, San Diego, CA, USA) and the SPSS
(Statsoft Inc, Tulsa, OK, USA) software. We used the χ2 or
Fisher’s exact test (two by two table) or χ2 test for trend
(larger contingency table), as appropriate, to compare cat-
egorical variables among the groups which had been cat-
egorized according to mutation load. The analysis of con-
tinuous variables among the groups was performed using
the Mann-Whitney U test or Kruskal-Wallis test with
Dunn’s method in the case of multiple comparisons.
Spearman’s rank non-parametric correlation test was per-
formed to analyze correlations between JAK2V617F allele
burden and hematologic parameters. Unconditional logis-
tic regression models with backward stepwise analysis
were used to identify factors that were associated with an
increased probability of having thrombotic events. A p
value of less than 0.05 was considered to indicate statisti-
cal significance; all tests were two-tailed. 
Results
Characteristics of the patients
We studied 260 subjects in whom a diagnosis of ET
was made based on WHO criteria; their clinical charac-
teristics and hematologic parameters at diagnosis, as
well as major clinical events associated with disease, are
reported in Table 1. Their median age was 52 years
(range, 16-93). Of these 260 subjects, 195 (75%) were
females, making the proportion of females higher than
that in most published series of ET; this was due to triv-
ial, uncontrolled reasons, and was not the result of a
selection. At diagnosis, 72 patients (28%) had
splenomegaly and in eight patients (3%) the spleen
diameter was greater than 15 cm. Twenty-three patients
(9%) reported aquagenic pruritus and 19 (7%) present-
ed with systemic symptoms. One hundred and sixty-
one patients (62%) required cytoreductive treatment,
either because they were high-risk patients, according
to current criteria,27 or because signs and/or symptoms
of myeloproliferation needed to be controlled. Fifty-six
patients (21%) had major thromboses, 26 of which
were detected at diagnosis or had occurred within the
preceding 2 years, and 25 during follow-up; five patients
had a second thrombotic event during follow-up. A
detailed description of the thrombotic events is present-
ed in Table 1. Microvessel symptoms were reported by
73 patients (28%). Hemorrhages affected 15 patients
(6%), and in all cases were gastrointestinal bleeds; seven
of these occurred at the time of diagnosis. The median
follow-up was 36 months (range, 1-120); during this
period four patients died of causes unrelated to their
hematologic disease, one patient developed myelofibro-
sis and two still-alive patients developed solid tumors.
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JAK2V617F mutational burden
The median time from diagnosis to blood sampling
for mutational analysis was 2.0 years (range, 0-3). DNA
samples for mutational analysis were collected at diag-
nosis in 102 patients (39%), within 1 year from diagno-
sis in 80 (31%), between 1 and 2 years from diagnosis in
50 (19%), while the remaining 28 patients (11%) were
genotyped from 2 to 3 years after diagnosis. According
to ASO PCR, 157 patients (60%) carried JAK2V617F muta-
tions, of whom 151 (96%) were considered heterozy-
gous and six (4%) homozygous, accounting for 58%
and 2% of the entire patient population, respectively.
However, by using QRT-PCR, the frequency of patients
with the mutation rose to 63% (n=165) and the percent-
age of those displaying >51% mutant alleles was 5%.
The median JAK2 mutant allele ratio in these 165
patients with the mutation was 24% (range, 1-87%),
which is significantly lower than the level we previous-
ly found in PV patients (n=173, 52% range 1-100%)21 or
in patients with PMF (n=55; 8%: range, 1-100%) or sec-
ondary forms of myelofibrosis (n=20; 61%: range, 1-
100%) (p<0.001 for all) (Figure 1). JAK2V617F levels ranged
from 1% to 25% in 101 patients (39%), from 26% to
50% in 51 patients (20%), from 51% to 75% in 10
patients (4%) while only three patients (1%) had
JAK2V617F levels greater than 75% (Figure 1).
Correlation of JAK2V617F burden with hematologic
parameters
Patients with the JAK2V617F mutant allele had signifi-
cantly higher leukocyte counts (p=0.02), hemoglobin
concentration (p<0.0001), hematocrit (p<0.0001), alka-
line phosphate level (p=0.04) and lower platelet count
(p=0.03), as compared to wild-type patients (Table 1).
However, there was no clear dose-dependent correla-
tion between these hematologic parameters, considered
either at diagnosis or at the time of blood sampling, and
the burden of JAK2 mutant allele (not shown in detail).
EEC formation was detected in 52% of evaluated
patients (n=113), accounting for 40% and 60% of
JAK2V617F wild-type and mutant patients, respectively
(p=0.05). We observed a significant correlation between
EEC and load of JAK2 mutant allele (p=0.0019) (Table 2);
indeed, all 13 patients with more than 50% mutant alle-
les displayed EEC formation as compared to half of
those with 1-25% V617F alleles. XCIP analysis was per-
formed in 122 patients, and was informative in 104
(85%); 11 females were excluded because of constitu-
tional skewing and seven because of homozygosity at
the HUMARA locus. Sixty-five per cent of informative
females had clonal hematopoiesis. The frequency of
patients with clonal hematopoiesis was similar among
those with wild-type (68%) or mutant JAK2V617F (63%);
furthermore, there was no difference in JAK2V617F mutant
allele load between patients with clonal or polyclonal
hematopoiesis (13% in both groups). Finally, we found
no significant correlation between PRV-1 expression
Table 1. Hematologic and clinical features at diagnosis in the 260
patients with ET considered in the study. 
JAK2V617F
All patients Wild-type pts Mutated pts p
(n=260) (n=95) (n=165)
Male/female 65/195 26/69 39/126 NS
Disease duration 36 (1-120) 39 (1-120) 30 (1-120) NS
(months)°
Age (yrs)° 52 (16-93) 50 (16-87) 55 (19-93) =0.005
Hematologic parameters
Hematocrit (%)§ 42±4 41±4 43±4 <0.0001
Hemoglobin (gr/dL)§ 14.0±1.4 13.4±1.3 14.4±1.3 <0.0001
MCV (fL)§ 87±4 88 ± 6 87±8 NS
White cell count (x109/L)§ 9.3±3.1 8.8±3.0 9.5±3.2 =0.02
Platelet count (x109/L)§ 880±314 959±380 835±260 =0.03
Lactate dehydrogenase (U/L)§ 351±167 347±137 353±180 NS
ALP (Arbitrary Units)§ 130±54 111±45 138±56 =0.04
Clinical characteristics
Splenomegaly (%) 72 (28%) 23 (24%) 49 (29%) NS
Splenomegaly >15 cm (%) 8 (3%) 1 (1%) 7 (4%) NS
Pruritus (%) 23 (9%) 9 (9%) 14 (8%) NS
Systemic symptoms (%) 19 (7%) 6 (6%) 13 (8%) NS
Cytoreductive therapy 161 (62%) 56 (59%) 105 (63%) NS
requirement (%)
Patients with major 56 (21%) 16 (17%) 40 (24%) NS
thrombotic events (%)
Patients with major 30 (11%) 8 (8%) 22 (13%) NS
arterial thrombosis (%)
Patients with major 26 (10%) 8 (8%) 18 (11%) NS
venous thrombosis (%)
Patients with thrombosis 31 (12%) 8 (8%) 23 (14%) NS
at diagnosis (%)
Patients with thrombosis 25 (10%) 8 (8%) 17 (10%) NS
during follow-up (%)
Patients with microvessels 73 (28%) 18 (19%) 55 (33%) =0.01
disease (%)
Patients with major 15 (6%) 4 (4%) 11 (6%) NS
hemorrhages (%)
°:Median value (range) is reported; §: mean value (±SD) is reported.
NS: not statistically significant. MCV: mean corpuscular volume;
ALP: alkaline phosphatase.
Figure 1. JAK2V617F allele burden in the 165 patients with the JAK2
mutation included in the study. For comparison, results from
patients with PV (n=135)44, primary myelofibrosis (PMF) (n=55) or
secondary forms of myelofibrosis (Post-MF) (n=20) are presented.
The level found in ET patients was significantly lower than the lev-
els in all other MPD categories (p<0.001). Boxes represent the
interquartile range that contains 50% of the subjects, the small
square inside the mean value, and the horizontal line inside
marks the median; the bars show the upper and lower range of
values.
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level and JAK2V617F allele burden, although the level of
PRV-1 was significantly lower in ET patients with the
wild-type genotype than in the ET patients with the
mutation (1.23±0.15 and 1.14±0.12, respectively;
p=0.03) (Table 2). In 74 patients, the three tests (EEC,
PRV-1 and XCIP) were concurrently evaluated; overall
concordance was found in only 25% of the cases, which
comprised nine and ten patients who had all of the tests
positive or negative, respectively. 
Correlation of JAK2V617F burden with clinical
characteristics
Patients with the JAK2V617F mutation were older than
those with wild-type alleles (p=0.005), and the mutant
allele load progressively increased in older patients
(Figure 2) (p<0.0001; 95% CI 0.16-0.44, Spearman’s rank
test). In contrast, the median disease duration was
inversely related to patients’ age: it was 42, 60, 27 and
18 months in patients less than 50 years old, 51-60 and
61-70 years old, or older than 70 years, respectively
(p<0.001).
Splenomegaly was equally present among patients
with or without the JAK2V617F mutation (29% and 24%,
respectively; p=0.8); however, median allele burden was
significantly higher (27% versus 20% p=0.04) in
patients who had splenomegaly as well as in those with
a larger spleen (30% versus 20%, p=0.03). Furthermore,
there was a correlation between greater JAK2V617F allele
burden and the frequency of patients who had either
splenomegaly (p=0.03, χ2 test for trend; Figure 3) or a
larger spleen (p=0.02, χ2 test for trend). The relative risk
(RR) of having splenomegaly was 2.2 (95% CI 1.2-4.1,
p=0.03) in the presence of greater than 50% V617F allele
using patients with wild-type alleles as the reference
population.
There was no difference between patients with muta-
tions or wild-type alleles as regards the frequency of
total (arterial plus venous) thrombotic events, which
affected 24% and 17% of the patients, respectively
(p=0.3), either considering thrombosis at diagnosis
(14% and 8%) or in the follow-up (10% and 8%,
respectively). The mutant allele burden was similar in
patients who did or did not have thrombosis (21% and
22%, respectively). However, when arterial and venous
events were considered separately, it was found that
allele burden was significantly higher in patients with
arterial thrombosis at diagnosis (33% versus 20%;
p=0.005), and that the frequency of patients with
thrombosis progressively increased with greater allele
burden (p=0.003, χ2 test for trend). The RR for arterial
thrombosis at diagnosis in patients with greater than
25% mutant allele was 3.0 (95% CI, 1.3-6.8; p=0.01).
The impact of V617F mutant allele burden on arterial
thrombosis at diagnosis was mantained in multivariate
analysis, which included age, leukocyte count, hemo-
globin and platelet count as co-variates (p=0.04). On the
other hand, there was no difference between patients
with mutant and wild-type alleles as regards the rate
with venous events (Table 1) nor there was any mean-
ingful effect of allele burden (not shown in detail).
Symptoms due to microvessel involvement affected
patients with and without JAK2V617F mutations similarly
(26% and 20%, respectively; p=0.27); however, when
patients were categorized according to their V617F allele
burden, the RR of suffering symptoms from microvessel
disease increased progressively (p=0.0008, χ2 test for
trend; Figure 3), being 2.2 (95%CI 1.3-3.8; p=0.03) and
2.4 (95% CI 1.2-5.0; p=0.03) in patients with a mutant
Table 2. Relationships between JAK2V617F allele burden and percentage
of patients with abnormal results of laboratory assays. 
Wild-type JAK2V617F p= JAK2V617F allele burden p§=
1-25% 26-50% 51-100%
EEC+VE 40% 60% 0.05 52% 81% 100% 0.0019
(59/105) (18/45) (41/60) (19/36) (9/11) (13/13)
XCIP+VE 68% 63% NS 62% 70% 50% NS
(68/104) (30/44) (38/60) (30/48) (7/10) (1/2)
PRV-1+VE 40% 49% NS 47% 46% 66% NS
(63/138) (21/52) (42/86) (32/67) (6/13) (4/6)
PRV-1 Levels 1.23 1.14 0.03 1.14 1.16 1.08 NS
±0.15 ±0.12 ±0.12 ±0.10 ± 0.16
EEC+VE indicates patients showing erythropoietin-independent erythroid colony
formation; XCIP+VE indicate females presenting clonal hematopoiesis based on the
HUMARA assay; for the definition of PRV-1 over-expression, refer to the Design and
Methods section. The total number of patients evaluated was 105, 104, and 138,
respectively. The number of patients positive for each marker over total number of
patients analyzed is shown within brackets in each row. §the p values indicates
difference among the three categorized groups of patients with the V617F mutation
according to the analysis of trend (χ2 test for trend or Kruskal-Wallis test with the use
of Dunn’s method for multiple comparisons, as appropriate).
NS: not statistically significant. 
Figure 2. JAK2V617F allele burden in different age groups. The 165
patients with JAK2 mutation were divided in four age classes, as
indicated. The age classes comprised 67, 29, 33, and 36 patients.
The JAK2 mutant allele burden in the two oldest age classes was
significantly different from that measured in patients less than 60
years old (p=0.01 for the 61-70 year old class, and p=0.0006 for
the >70 year old age class). Boxes represent the interquartile
range that contains 50% of the subjects, the horizontal line inside
marks the median, the small square inside the mean value, and
bars show the upper and lower range of values.
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allele burden greater than 25% and 50%, respectively.
Finally, the mutant allele burden had no impact on
pruritus, systemic symptoms, need for cytoreductive
treatment, duration of disease or occurrence of hemor-
ragic events (not shown in detail).
Kinetics of JAK2V617F allele burden
Changes in JAK2V617F allele level measured at diagnosis
were evaluated in 35 patients for whom at least one
additional sample, taken during follow-up over a medi-
an time of 18 months (range, 6-36 months), was avail-
able. None of the 20 patients who had JAK2V617F wild-
type alleles at diagnosis became positive for the muta-
tion. Twelve out of the 15 patients with the mutation
maintained stable V617F allele levels during follow-up,
the median difference among samples being 5% (range,
1-12%). On the other hand, three patients showed overt
changes in their mutant allele burden; in two of them
V617F allele levels decreased from 22% and 29% to 4%
and 3%, respectively, during treatment with hydrox-
yurea. However, an additional four patients receiving
hydroxyurea did not show appreciable changes of allele
burden over time. The third patient presented an
increase from 82% to 100% of V617F allele in spite of
cytoreductive treatment with hydroxyurea and a purine
analog, which was instituted because of progressive
leukocytosis with erythroblastosis, accompanied by the
onset of transfusion-dependent anemia, suggestive of
transformation to post-thrombocythemic myelofibrosis
(the patient refused to undergo a bone marrow biopsy).
Discussion
Among the chronic myeloproliferative disorders, ET
is characterized by greatest heterogeneity both as
regards its clinical profile and at the cellular and molec-
ular levels, since at least one third of females with ET
have apparently polyclonal hematopoiesis,28-32 although
there may be pitfalls in the interpretation of clonality
assays;33 in addition, only 50 to 60% of patients have
the JAK2V617F mutation, while a minority (1%) harbor
MPL mutations.34 Current data about the prognostic rel-
evance of the JAK2V617F mutation in patients with ET are
still partially inconclusive. The presence of the mutation
has been associated with venous thrombosis occurring
in the years before diagnosis in a large series,11 while in
other studies no such correlation was found.12,35
Furthermore, in a comparative analysis of patients with
ET and PV, ET patients with mutations had significant-
ly more thrombotic events than their wild-type counter-
part, and did not differ under this respect from PV
patients.17 Intriguingly, the JAK2V617F mutation was
recently reported as being an independent risk factor for
fetal loss in ET females.36 Finally, in a large multicenter
study, ET patients harboring homozygous JAK2V617F
mutation had a 3.9-fold higher risk of major cardiovas-
cular events as compared to both their heterozygous
and wild-type counterparts.13
In this study, we employed a quantitative RT-PCR
assay to measure JAK2V617F alleles in 260 ET patients
with the aim of evaluating whether the mutant allele
load affected hematologic and clinical phenotype, possi-
bly overcoming limitations of the qualitative assays that
had been employed in previous studies. We were
prompted to do this by our recent study in PV patients
which showed that the extent of hematologic abnor-
malities and of some major clinical manifestations, in
particular thrombosis and chemotherapy need, were
actually dependent on the burden of V617F allele meas-
ured in granulocytes collected at diagnosis.21 However,
Figure 3. Effect of JAK2V617F allele burden on clinical outcomes in
ET patients. The analysis was performed to calculate the relative
risk of a patient presenting with splenomegaly (upper panel),
developing major thrombotic events (middle panel) or having
microvessel disease (lower panel) according to the amount of
JAK2 mutant allele. Squares indicate the relative risk along with
the 95% confidence interval (vertical bars). The reference catego-
ry was patients who were wild-type (WT) for the mutation. 
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another study in PV patients from the Mayo Clinic
found no significant correlation between allele burden
and clinical manifestations;37 a different source of DNA
(bone marrow instead of granulocytes) and the fact that
patients in this study were examined variably during
follow-up rather than at diagnosis might underlie these
discrepancies.
Consistent with previous data, ET patients with
JAK2V617F mutation had higher erythrocyte and leuko-
cyte counts, and reduced platelet levels; however, the
extent of these abnormalities was not significantly
dependent on the burden of mutant alleles. Similar find-
ings were reported in a recent paper by Tefferi’s group,
in which 96 ET patients with mutations were analyzed
using a quantitative assay.38 Intriguingly, these results
differ from those we reported for PV patients,21 in
whom abnormalities in hematologic parameters were
dose-dependently correlated with V61F allele burden.
We hypothesize that this different behavior might be
accounted for by the significantly lower burden of
mutant alleles actually present in the ET patients (Figure
1), which prevented a direct cause-effect relationship
from being revealed. This statement is indirectly sup-
ported by the finding that the percentage of ET patients
displaying EEC formation (a phenomenon which is a
very sensitive indicator of autonomous activation of the
JAK-STAT pathway)39 progressively increased depend-
ing on the amount of mutant allele. Also, no correlation
was found between either the presence or burden of
V617F allele with clonal hematopoiesis by XCIP analy-
sis40 or PRV-1 expression level.41 Finally, patients with
the JAK2V617F mutation were older than those with wild-
type alleles,11,13,15 and the load of mutant allele progres-
sively increased with age. 
Confirming previous observations,42 we found that
none of patients who had wild-type alleles at diagnosis
later became positive, while we report some decrease of
allele burden in three out of seven patients who were
receiving hydroxyurea treatment. Given the low num-
ber of patients evaluated, we cannot draw any firm con-
clusions from these findings, which might have been
non-specific unlike those reported in PV patients receiv-
ing interferon-a.43
The categorization of subjects according to the load of
V617F allele measured by QRT-PCR in their granulocytes
allowed us to reveal some effects that had been other-
wise masked by the analysis of mutated versus wild-type
patients considered as a whole. In fact, we observed that
splenomegaly was significantly more frequent in patients
having greater than 50% of the mutant allele, while
symptoms due to microvessel disease were over-repre-
sented when the mutant allele level was just over 25%.
Furthermore, we found that there was a 3-fold greater
risk of arterial thrombosis at diagnosis in patients with
more than 25% V617F allele, even though the difference
between patients with the mutation and wild-type
patients all together had not attained statistical signifi-
cance. At variance with other studies, we found no asso-
ciation between the presence of mutant alleles and
venous events,11 but this is likely because of the low num-
ber of subjects who had venous thrombosis in our series.
Overall, these observations in ET add to the growing
idea that hematologic abnormalities, as well as defined
aspects of clinical phenotype, in MPD patients are at
least partially related to the relative representation of
the V617F allele in the context of normal hematopoiesis;
this would also help to explain why JAK2V617F-associated
abnormalities are seen more clearly in patients with
PV21,45 or primary myelofibrosis,16 whose median allele
burden is substantially greater than that of ET patients.
However, whether JAK2V617F mutant status and/or allele
burden might be fruitfully employed as novel criteria for
risk stratification in patients with ET requires controlled
prospective trials.
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